Abstract
The growing diffusion of life support procedures, including cardiopulmonary resuscitation (CPR) and advanced cardiac life support (ACLS), allows physicians to keep a person alive almost indefinitely when the person's heart has stopped beating autonomously or spontaneous breathing is precluded. However, in some cases patients are brought back to life but remain in a vegetative state (VS) or in a minimally conscious state (MCS). This prompts reflections on the ‘pros and cons’ of life support procedures and on the recommended conduct to be adopted for the general management of patients who survive in a VS or MCS. Important issues to be debated include the choice of therapeutic management which guarantees for the patient the maximum possible physical and mental well-being; the distinction between ‘worthwhile’ and ‘disproportionate’ treatments; the patient's right to make decisions concerning his or her own health status; the possibility to make ‘advance directives’ when still healthy or when a life-threatening illness has been diagnosed; the role of relatives and caregivers in the choice of the best treatment for unconscious patients and the identification of ethically and scientifically valid criteria for the inclusion of unconscious patients in studies investigating experimental therapies.
Keywords: Disorders of consciousness, vegetative state, minimally conscious state, ethical, care, consent.
Current Pharmaceutical Design
Title:Ethical Aspects of Vegetative and Minimally Conscious States
Volume: 20 Issue: 26
Author(s): Pierre Mallia, Raffaele Daniele, Simona Sacco, Antonio Carolei and Francesca Pistoia
Affiliation:
Keywords: Disorders of consciousness, vegetative state, minimally conscious state, ethical, care, consent.
Abstract: The growing diffusion of life support procedures, including cardiopulmonary resuscitation (CPR) and advanced cardiac life support (ACLS), allows physicians to keep a person alive almost indefinitely when the person's heart has stopped beating autonomously or spontaneous breathing is precluded. However, in some cases patients are brought back to life but remain in a vegetative state (VS) or in a minimally conscious state (MCS). This prompts reflections on the ‘pros and cons’ of life support procedures and on the recommended conduct to be adopted for the general management of patients who survive in a VS or MCS. Important issues to be debated include the choice of therapeutic management which guarantees for the patient the maximum possible physical and mental well-being; the distinction between ‘worthwhile’ and ‘disproportionate’ treatments; the patient's right to make decisions concerning his or her own health status; the possibility to make ‘advance directives’ when still healthy or when a life-threatening illness has been diagnosed; the role of relatives and caregivers in the choice of the best treatment for unconscious patients and the identification of ethically and scientifically valid criteria for the inclusion of unconscious patients in studies investigating experimental therapies.
Export Options
About this article
Cite this article as:
Mallia Pierre, Daniele Raffaele, Sacco Simona, Carolei Antonio and Pistoia Francesca, Ethical Aspects of Vegetative and Minimally Conscious States, Current Pharmaceutical Design 2014; 20 (26) . https://dx.doi.org/10.2174/13816128113196660655
DOI https://dx.doi.org/10.2174/13816128113196660655 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Copper in Prion Diseases: Deleterious or Beneficial?
Current Pharmaceutical Design Reciprocal Interactions Between Wakefulness and Sleep Influence Global and Regional Brain Activity
Current Topics in Medicinal Chemistry Congenital Cytomegalovirus Infection: An Overview
Infectious Disorders - Drug Targets Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury
Current Neurovascular Research Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Cognitive Dysfunction in FMR1 Premutation Carriers
Current Psychiatry Reviews Screening for Inhibitors of Microglia to Reduce Neuroinflammation
CNS & Neurological Disorders - Drug Targets Editorial
Current Radiopharmaceuticals N-acetyl-cysteine in Schizophrenia: Potential Role on the Sensitive Cysteine Proteome
Current Medicinal Chemistry Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?
Current Alzheimer Research Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Current Topics in Medicinal Chemistry The Role of Peroxisome Proliferator-Activated Receptor-γ in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry New Highlights in the Regulation of Cells Proliferation
Neuroscience and Biomedical Engineering (Discontinued) Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Impacting Neuronal and Vascular Cellular Signal Transduction through the Metabotropic Glutamate Receptor System
Medicinal Chemistry Reviews - Online (Discontinued) Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design